Please assess the completion status of the following clinical trial:

Trial Title: Sunitinib and Capecitabine for First Line Colon Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed, newly diagnosed metastatic colorectal cancer~* Measurable or evaluable disease in which surgical resection with curative intent is not possible~* No adjuvant chemotherapy within 6 months of enrollment~* No prior sunitinib or other receptor tyrosine kinase inhibitors~* 18 years of age or greater~* Anticipated survival of at least 6 months~* Ambulatory with an ECOG performance status of 0 or 1 and able to maintain weight~* Normal organ and marrow function~* Must agree to avoid pregnancy or fathering a child through out study participation~* Ability to understand and willingness to sign a written informed consent document~Exclusion Criteria:~* Chemotherapy or radiotherapy within 6 months of enrollment~* Receiving any other investigational agents~* Known untreated brain metastases, uncontrolled seizure disorders, encephalitis, or multiple sclerosis~* Not able to ingest oral medications with normal absorption from the GI tract~* Uncontrolled hypertension~* History of severe/unstable angina, heart attack, congestive heart failure, transient ischemic attack, or stroke within 6 months of enrollment~* Cardiac dysrhythmias~* History of clinically significant bleeding within the past 6 months, including gross hemoptysis or hematuria, or underlying coagulopathy~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of study enrollment~* Current treatment with therapeutic doses of coumadin~* Concurrent malignancy other than colorectal cancer~* Known dihydropyrimidine dehydrogenase deficiency~* Uncontrolled intercurrent illness including ongoing or active infection or psychiatric illness that would limit compliance with study requirements.~* Pregnant and nursing women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- sunitinib and cepecitabine (Type: EXPERIMENTAL): Administration of sunitinib and capecitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).